ImClone/Bristol Due Diligence Lesson: FDA Review Divisions Need Closer Look
Executive Summary
Changes at FDA review divisions deserve closer scrutiny as part of due diligence efforts for in-licensing deals, panelists at a BIO/Windhover conference in Washington D.C. suggested